{"prompt": "['MC1575', '49', 'Amendment 2', 'Excretion: Following administration of radiolabeled lenvatinib to 6 subjects with', 'solid tumors, approximately two-thirds and one-fourth of the radiolabel were', 'eliminated in the feces and urine, respectively.', 'Special populations: No dose adjustments are required on the basis of hepatic', 'function in patients with mild (Child-Pugh A) or moderate (Child-Pugh B)', 'hepatic impairment. In patients with severe', '(Child Pugh C) hepatic impairment, the starting dose should be lowered. No dose', 'adjustments are required on the basis of renal function in patients with mild or', 'moderate renal impairment. In patients with severe renal impairment, the starting', 'dose should be lowered. Further dose adjustments may be necessary on the basis', 'of individual tolerability.', '15.16', 'Potential Drug Interactions: In vitro, cytochrome P450 3A4 was the', 'predominant (>80%) cytochrome isoform involved in the P450-mediated', 'metabolism of lenvatinib. In vivo, inducers and inhibitors of CYP3A4 had', 'a minimal effect on lenvatinib exposure. Lenvatinib is not considered a', \"strong inducer or inhibitor of cytochrome P450 or uridine 5'-diphospho-\", 'glucuronosyl transferase (UGT) enzymes. Lenvatinib may be co-', 'administered without dose adjustment with CYP3A, P-glycoprotein (P-', 'gp), and BCRP inhibitors or CYP3A and P-gp inducers.', '15.17 Known potential adverse events:', 'Common known potential toxicities, >10%:', 'Gastrointestinal disorders: Abdominal pain, diarrhea, nausea, vomiting', 'General disorders and administrative site conditions: Asthenia', 'Metabolism and nutrition disorders: Decreased appetite, dehydration', 'Renal and urinary disorders: Acute kidney injury', 'Vascular disorders: Hypertension', 'Less common known potential toxicities, 1%-10%:', 'Metabolism and nutrition disorders: dehydration', 'Respiratory, thoracic, and mediastinal disorders: pulmonary embolism', 'Vascular disorders: hypotension', 'Rare known potential adverse events, <1% (Limited to important or life-', 'threatening):', 'Blood and lymphatic disorders: Thrombocytopenia', 'Cardiac disorders: Acute myocardial infarction, myocardial infarction, cardiac', 'failure, congestive cardiac failure, coronary artery occlusion, left ventricular', 'dysfunctionon', 'Endocrine disorders: hypothyroidism', 'Gastrointestinal disorders: abdominal pain lower, abdominal pain upper, anal', 'fistula, constipation, diverticular perforation, intestinal perforation, pancreatitis,', 'acute pancreatitis, rectal hemorrhage, rectal perforation, stomatitis, upper', 'gastrointestinal hemorrhage', 'Hepatobiliary disorders: Cholecystitis, cholecystitis acute, hepatic failure,', 'hepatic function abnormal, hepatitis acute, hyperbilirubinemia, liver injury', 'Infections and infestations: Colonic abscess, perineal abscess, urinary tract', 'infection, urosepsis', 'Protocol Version Date:16Aug2018']['MC1575', '50', 'Amendment 2', 'Investigations: Alanine aminotransferase increased, aspartate aminotransferase', 'increased, blood bilirubin increased, ejection fraction increased, lipase increased,', 'weight decreased', 'Metabolism and nutrition disorders: Hypocalcemia, hypokalemia,', 'hypomagnesemia', 'Musculoskeletal and connective tissue disorders:', 'Neoplasms benign, malignant and unspecified: Intracranial tumor hemorrhage,', 'tumor hemorrhage', 'Nervous system disorders: Cerebral hemorrhage, cerebral infarction,', 'cerebrovascular accident, dizziness, hemorrhage intracranial, headache, ischemic', 'stroke, monoparesis,, reversible posterior leukoencephalopathy syndrome,', 'subarachnoid hemorrhage, transient ischemic attack', 'Renal and urinary disorders: Hematuria, proteinuria, renal failure, renal', 'impairment, renal tubular necrosis', 'Reproductive system and breast disorders: Female genital tract fistula, vaginal', 'hemorrhage', 'Respiratory, thoracic, and mediastinal disorders: Epistaxis, hemoptysis,', 'pulmonary hemorrhage', 'Vascular disorders: Hypertensive crisis', '15.18', 'Drug procurement', 'Each participating site will order/monitor drug supply through Eisai Inc.', 'NOTE: Outdated or remaining drug is to be destroyed on-site per procedures in', 'place at each institution.', '15.19 Nursing guidelines', '15.191', 'Hypertension is very common with agent. Monitor BP as per protocol', 'and report BP elevations to the study team.', '15.192', 'Diarrhea is common. This may be increased in patients who are', 'undergoing simultaneous treatment with immunotherapy agents.', 'Instruct patients to report any diarrhea immediately and treat', 'symptomatically per protocol instructions.', '15.193', 'Other GI side effects can occur, including decreased appetite, weight', 'loss, and nausea/vomiting. Manage patient symptomatically and', 'monitor for effectiveness.', '15.194', 'Patients may experience fatigue. Instruct patients in energy conserving', 'lifestyle.', '15.195', 'Dermatologic related side effects have been seen, including: hand-foot', 'syndrome, rash, and alopecia. Instruct patients to report these signs and', 'symptoms to the study team immediately.', '15.196', 'Patients may experience increased risk of bleeding. Instruct patients to', 'report any unusual bruising or bleeding to the study team. Patients', 'should not undergo invasive procedures without first discussing with', 'the study team.', '15.197', 'Monitor for proteinuria per protocol.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}